Selexipag: A New Treatment Agent for Pulmonary Arterial Hypertension
Clicks: 186
ID: 105605
2019
Pulmonary arterial hypertension (PAH) is a rare disease which is characterized by the progressive increase of pulmonary arterial pressure. PAH can lead to right cardiac insufficiency and death. Conventional and other treatment modalities that target the physiopathological and etiopathological causes of the disease are currently being used. Selexipag is an oral selective prostacyclin receptor agonist which was developed to overcome the pathophysiological mechanisms that play role in the PAH.
| Reference Key |
yazici2019selexipagmeandros
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yazıcı, Onur;Güngör, Hasan; |
| Journal | meandros medical and dental journal |
| Year | 2019 |
| DOI | DOI not found |
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.